Kenneth C. Anderson, MD
In updated guidelines exploring the role of bone-modifying agents, the American Society of Clinical Oncology (ASCO) has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.1
Table. Denosumab Demonstrates Noninferiority to Zoledronic Acid in Time to First Skeletal Event5
Dosing Changes Discussed
The updated guidelines also discuss the feasibility of less-frequent dosing of bone-targeted treatments in selected patients, given the risk of osteonecrosis of the jaw (ONJ) associated with bone-targeting agents. Study results have shown that less-frequent dosing can reduce the risk.
... to read the full story